Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyBCBSRI Microorganism Probe Coverage | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Identification of Microorganisms Using Nucleic Acid Probes

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage, medical necessity, and prior authorization for specified nucleic acid probe tests and panels used to identify or quantify microorganisms for Medicare Advantage Plans and Commercial Products, subject to the member's benefit plan.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyIdentification of Microorganisms Using Nucleic Acid Probes
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 202613d
    Last ReviewAug 19, 2026
    Next Review DateN/A
    Key ActionParticipating providers must meet the applicable medical criteria in the online authorization tool for coverage of the listed tests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Specific tests addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    27Eligible microorganisms without viral-load quantification
    6Eligible microorganisms with or without viral-load quantification
    2Excluded microorganism indications
    2Excluded pathogen panels

    Coverage Criteria

    Specified Tests

    The following tests are considered medically necessary when the medical criteria in the online authorization tool for participating providers are met.

    ONE of the following tests

    • ePlex BCID Fungal Pathogens Panel (CPT code 0140U)
    • ePlex BCID Gram-Positive Panel (CPT code 0141U)
    • ePlex BCID Gram-Negative Panel (CPT code 0142U)
    • MicroGenDX qPCR & NGS For Infection (CPT code 0112U)

    Direct or Amplified Probes Without Viral-Load Quantification

    The use of nucleic acid testing using a direct or amplified probe technique, without quantification of viral load, may be considered medically necessary for the following microorganisms.

    ONE of the following microorganisms

    • Bartonella henselae or quintana
    • Bordetella pertussis
    • Candida species
    • Chlamydia pneumoniae
    • Chlamydia trachomatis
    • Clostridium difficile
    • Enterococcus, vancomycin-resistant (e.g., enterococcus vanA, vanB)

    Direct or Amplified Probes With or Without Viral-Load Quantification

    The use of nucleic acid testing using a direct or amplified probe technique, with or without quantification of viral load, may be considered medically necessary for the following microorganisms.

    ONE of the following microorganisms

    • Cytomegalovirus
    • Hepatitis B virus
    • Hepatitis C virus
    • HIV-1
    • HIV-2
    • Human herpesvirus 6

    Respiratory Virus Panel

    The use of the following nucleic acid testing panel, without quantification of viral load, may be considered medically necessary.

    Respiratory virus panel

    Not Covered or Not Medically Necessary

    The following indications are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products because the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

    ALL of the following

    • Nucleic acid testing with quantification of viral load for microorganisms not included in the listed microorganisms for which direct or amplified probes with or without quantification are medically necessary.
    • Direct or amplified probe nucleic acid testing for Gardnerella vaginalis or Hepatitis G.
    • Nucleic acid testing panels, with or without quantification of viral load for viral panel elements, for central nervous system pathogen panels or gastrointestinal pathogen panels.

    Medical Necessity Criteria

    Coverage for the following CPT codes depends on meeting the applicable medical criteria in the online authorization tool for participating providers.

    ONE of the following covered services

    • ePlex BCID Fungal Pathogens Panel — CPT code 0140U
    • ePlex BCID Gram-Positive Panel — CPT code 0141U
    • ePlex BCID Gram-Negative Panel — CPT code 0142U
    • MicroGenDX qPCR & NGS For Infection (MicroGenDX) — CPT code 0112U: Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene

    Direct or amplified probe nucleic acid testing for Gardnerella vaginalis and Hepatitis G is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

    Nucleic acid testing panels for central nervous system pathogens and gastrointestinal pathogens, with or without quantification of viral load for viral panel elements, are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

    Nucleic acid testing with quantification of viral load for microorganisms not included in the listed microorganisms for which direct or amplified probes with or without quantification are medically necessary is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

    The exclusions described above apply to Commercial Products as statements of medical necessity and to Medicare Advantage Plans as coverage determinations. Effective December 1, 2026, the specified ePlex panels and MicroGenDX testing may be medically necessary for both Medicare Advantage Plans and Commercial Products when the applicable online authorization tool criteria are met.

    Laboratories are not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician may be involved in prior authorization, appeal, or other administrative processes related to prior authorization or medical necessity.

    Coding and Covered Services

    Policy-addressed nucleic acid probe testsCPTCovered
    0112UMicroGenDX qPCR & NGS For Infection (MicroGenDX)
    0140UePlex BCID Fungal Pathogens Panel (GenMark Diagnostics, Inc.)
    0141UePlex BCID Gram-Positive Panel (GenMark Diagnostics, Inc.)
    0142UePlex BCID Gram-Negative Panel (GenMark Diagnostics, Inc.)
    CPT codes that may be considered medically necessaryCPTCovered
    0140UePlex BCID Fungal Pathogens Panel
    0141UePlex BCID Gram-Positive Panel
    0142UePlex BCID Gram-Negative Panel
    Medically necessary CPT code for MicroGenDX qPCR & NGS For InfectionCPTCovered
    0112UInfectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene

    Authorization and Provider Responsibilities

    Prior Authorization

    ePlex Panel Authorization

    Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products through the online authorization tool for participating providers.

    • ePlex BCID Fungal Pathogens Panel — CPT 0140U
    • ePlex BCID Gram-Positive Panel — CPT 0141U
    • ePlex BCID Gram-Negative Panel — CPT 0142U
    Prior Authorization

    MicroGenDX Authorization Required

    Prior authorization is required for the MicroGenDX proprietary laboratory analysis test.

    • MicroGenDX qPCR & NGS For Infection — CPT 0112U

    Clinical Background

    Nucleic acid probes detect microorganism DNA or RNA and can identify organisms rapidly, including organisms that are difficult or impossible to culture. Amplification methods such as PCR can increase detection sensitivity, while quantitative methods can measure nucleic acid levels and support serial assessment of treatment response. Potential clinical value includes faster diagnosis, diagnosis when standard culture is difficult, and information that changes treatment or other clinical management; results may also be affected by false-positive or false-negative findings, inaccurate pathogen identification or interpretation, and incorrect test operation.

    Technical Definitions

    Direct probe technique
    DefinitionDetects microorganism nucleic acids without an initial amplification step.
    Target materialDetects genetic material such as RNA or DNA.
    Sensitivity distinctionDirect assays generally have lower sensitivity than amplified probes.
    Amplified probe technique
    DefinitionUses target, probe, or signal amplification to improve assay sensitivity over direct probe techniques without quantifying nucleic acid amounts.
    Target amplification methodsInclude polymerase chain reaction (PCR), nucleic acid-based sequence amplification, transcription-mediated amplification, and strand displacement amplification.

    Covered Indications

    Direct or Amplified Probe Testing Without Viral-Load Quantification

    Direct or amplified probe testing without quantification of viral load may be considered medically necessary for any one of the following 27 microorganisms.

    Eligible microorganism: Testing may be medically necessary for Bartonella henselae or quintana; Bordetella pertussis; Candida species; Chlamydia pneumoniae; Chlamydia trachomatis; Clostridium difficile; vancomycin-resistant Enterococcus, such as vanA or vanB; Enterovirus; Herpes simplex virus; Human papillomavirus; Influenza virus; Legionella pneumophila; Mumps; Mycobacterium species; Mycobacterium tuberculosis; Mycobacterium avium-intracellulare; Mycoplasma genitalium; Mycoplasma pneumoniae; Neisseria gonorrhoeae; Rubeola (measles); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Staphylococcus aureus; methicillin-resistant Staphylococcus aureus; group A Streptococcus; group B Streptococcus; Trichomonas vaginalis; or Zika virus.

    The test must use a direct or amplified probe technique without viral-load quantification.

    Direct or Amplified Probe Testing With or Without Viral-Load Quantification

    Direct or amplified probe testing with or without quantification of viral load may be considered medically necessary for any one of the following six viruses.

    Ordering Requirements

    Prior Authorization

    Ordering requirements

    Only the ordering physician may obtain authorization, participate in appeals, or handle related administrative processes. Laboratories, laboratory-affiliated representatives, and third parties may not do so on the ordering physician’s behalf.

    Not Covered Services

    Gardnerella vaginalis and Hepatitis G nucleic acid testing using a direct or amplified probe technique are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products.

    Central nervous system pathogen panels and gastrointestinal pathogen panels, including viral panel elements with or without viral-load quantification, are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products.

    Quantitative viral-load testing for microorganisms outside the policy’s listed medically necessary indications is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyIdentification of Microorganisms Using Nucleic Acid Probes
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 202613d
    Last ReviewAug 19, 2026
    Next Review DateN/A
    Key ActionParticipating providers must meet the applicable medical criteria in the online authorization tool for coverage of the listed tests.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Covered ServicesAuthorization and Provider ResponsibilitiesClinical BackgroundTechnical DefinitionsCovered IndicationsOrdering RequirementsNot Covered Services
    Enterovirus
  1. Herpes simplex virus
  2. Human papillomavirus
  3. Influenza virus
  4. Legionella pneumophila
  5. Mumps
  6. Mycobacterium species
  7. Mycobacterium tuberculosis
  8. Mycobacterium avium-intracellulare
  9. Mycoplasma genitalium (MG)
  10. Mycoplasma pneumoniae
  11. Neisseria gonorrhoeae
  12. Rubeola (measles)
  13. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  14. Staphylococcus aureus
  15. Staphylococcus aureus, methicillin-resistant
  16. Streptococcus, group A
  17. Streptococcus, group B
  18. Trichomonas vaginalis
  19. Zika virus
  20. Documentation Required

    Ordering Physician Must Obtain Authorization

    Only the ordering physician may obtain clinical authorization or participate in the prior authorization, appeal, or related administrative process. Laboratories, laboratory-associated entities, their representatives, and third parties may not perform these functions on the physician’s behalf.

    Unsupported block type: prior_auth

    Documentation Required

    Ordering Physician Documentation Responsibility

    The ordering physician is responsible for all documentation related to authorization, appeals, and other administrative processes. This includes preparing the necessary documentation of clinical appropriateness; laboratories and third parties may not prepare or facilitate it.

    Documentation Required

    Medical Necessity Documentation

    Where applicable, the provider must document medical necessity by meeting the criteria in the online authorization tool for participating providers.

    • The criteria apply to the listed ePlex panels and MicroGenDX qPCR & NGS For Infection.
    • Clinical documentation should support the applicable medical-necessity criteria.
    Denial Risk

    Unauthorized Laboratory Service

    If a participating laboratory provides a laboratory service that was not authorized, the service will be denied as the laboratory’s financial liability and may not be billed to the member.

    • Laboratory or third-party support of the authorization process may violate policy and result in severe action, up to and including termination from the BCBSRI provider network.
    Denial Risk

    Excluded Tests and Indications

    The following testing is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products because evidence is insufficient to establish improvement in the net health outcome.

    • Central nervous system pathogen panels
    • Gastrointestinal pathogen panels
    • Gardnerella vaginalis testing
    • Hepatitis G testing
    Denial Risk

    Unlisted Quantitative Testing

    Nucleic acid testing with quantification of viral load outside the microorganisms and indications specifically listed as medically necessary is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

    • Applies to unlisted quantitative viral-load testing.
    • Coverage is limited to the policy’s listed microorganisms and applicable probe-based testing indications.
    Probe amplification methodLigase chain reaction is a probe amplification method.
    Signal amplification methodsInclude branched DNA (bDNA) probes and hybrid capture methods using an anti-DNA/RNA hybrid antibody.
    Probe with quantification
    DefinitionUses quantitative PCR or real-time PCR to generate absolute or relative amounts of a known nucleic acid sequence in the original sample.
    Measurement methodUses a reporter at each stage of PCR.
    Reporter optionsMay use DNA-specific dyes, hybridization probes, or primer-incorporated probes.
    Clinical useQuantification permits serial assessment of response to treatment; a common application is serial measurement of HIV RNA, or viral load.
    Nucleic acid probe
    DefinitionDetects and identifies species or subspecies of organisms by identifying nucleic acid sequences in a sample.
    Target materialDetects genetic materials such as RNA or DNA.
    Distinguishing featureIdentifies organisms through their nucleic acid sequences rather than through antigens or antibodies.
    Eligible virus:
    Testing may be medically necessary for Cytomegalovirus, Hepatitis B virus, Hepatitis C virus, HIV-1, HIV-2, or Human herpesvirus 6.

    Testing may be performed with or without viral-load quantification.

    Respiratory Virus Panel Without Viral-Load Quantification

    A respiratory virus panel may be considered medically necessary when both conditions are met.

    Respiratory panel criteria

    • The patient has signs and/or symptoms of respiratory infection.
    • The patient receives a nucleic acid-based respiratory pathogen panel without viral-load quantification.

      Evidence supports improved net health outcomes based on accuracy and improvements in time-to-treat, targeted antibiotic prescribing, or hospital length of stay.

    ePlex BCID Fungal, Gram-Positive, and Gram-Negative Panels

    The following panels may be considered medically necessary when the applicable authorization criteria are met.

    ePlex BCID panel authorization: The ePlex BCID Fungal Pathogens Panel, ePlex BCID Gram-Positive Panel, or ePlex BCID Gram-Negative Panel is ordered and the medical criteria in the online authorization tool for participating providers are met.

    Effective 12/1/2026 for Medicare Advantage Plans and Commercial Products.

    MicroGenDX qPCR & NGS For Infection

    MicroGenDX qPCR & NGS For Infection may be considered medically necessary when the applicable medical necessity criteria are met.

    MicroGenDX criteria: The applicable medical necessity criteria for MicroGenDX qPCR & NGS For Infection are met.

    Prior authorization is required. The applicable online authorization criteria must be met for CPT code 0112U.

    Respiratory Pathogen Panel for Patients With Signs or Symptoms of Respiratory Infection

    Coverage may be considered medically necessary when the following clinical and evidence-based conditions apply.

    Respiratory pathogen panel criteria

    • The patient has signs and/or symptoms of respiratory infection.
    • The patient receives a nucleic acid-based respiratory pathogen panel.

      The evidence includes a systematic review and randomized controlled trials showing high accuracy and benefits in time-to-treat, targeted antibiotic prescribing, or hospital length of stay.